Institute of Physiology and Pathophysiology, Friedrich-Alexander-University Erlangen-Nürnberg, Universitätsstr. 17, D-91054, Erlangen, Germany.
Department of Physiology, University of Szeged, Dóm tér 10, Szeged, H-6720, Hungary.
J Headache Pain. 2021 Sep 8;22(1):105. doi: 10.1186/s10194-021-01320-9.
Calcitonin gene-related peptide (CGRP) is released from activated meningeal afferent fibres in the cranial dura mater, which likely accompanies severe headache attacks. Increased CGRP levels have been observed in different extracellular fluid compartments during primary headaches such as migraine but it is not entirely clear how CGRP is drained from the meninges.
We have used an in vivo preparation of the rat to examine after which time and at which concentration CGRP applied onto the exposed parietal dura mater appears in the jugular venous blood and the cerebrospinal fluid (CSF) collected from the cisterna magna. Recordings of meningeal (dural) and cortical (pial) blood flow were used to monitor the vasodilatory effect of CGRP. In a new ex vivo preparation we examined how much of a defined CGRP concentration applied to the arachnoidal side penetrates the dura. CGRP concentrations were determined with an approved enzyme immunoassay.
CGRP levels in the jugular plasma in vivo were slightly elevated compared to baseline values 5-20 min after dural application of CGRP (10 μM), in the CSF a significant three-fold increase was seen after 35 min. Meningeal but not cortical blood flow showed significant increases. The spontaneous CGRP release from the dura mater ex vivo was above the applied low concentration of 1 pM. CGRP at 1 nM did only partly penetrate the dura.
We conclude that only a small fraction of CGRP applied onto the dura mater reaches the jugular blood and, in a delayed manner, also the CSF. The dura mater may constitute a barrier for CGRP and limits diffusion into the CSF of the subarachnoidal space, where the CGRP concentration is too low to cause vasodilatation.
降钙素基因相关肽(CGRP)是从颅顶硬脑膜中的激活脑膜传入纤维中释放出来的,这可能伴随着严重的头痛发作。在偏头痛等原发性头痛期间,不同的细胞外液隔室中观察到 CGRP 水平升高,但尚不清楚 CGRP 如何从脑膜中排出。
我们使用大鼠体内的一种制备方法,检查暴露的顶骨硬脑膜上施加的 CGRP 在多长时间后以何种浓度出现在颈内静脉血液和从枕大池收集的脑脊液(CSF)中。脑膜(硬脑膜)和皮质(软脑膜)血流的记录用于监测 CGRP 的血管舒张作用。在一个新的离体制备中,我们检查了施加到蛛网膜侧的特定 CGRP 浓度有多少渗透到硬脑膜中。使用批准的酶免疫测定法确定 CGRP 浓度。
与基线值相比,体内颈内静脉血浆中的 CGRP 水平在硬脑膜应用 CGRP(10 μM)后 5-20 分钟略有升高,在 CSF 中 35 分钟后观察到显著的三倍增加。脑膜但不是皮质血流显示出显著的增加。从硬脑膜离体自发释放的 CGRP 高于应用的低浓度 1 pM。1 nM 的 CGRP 仅部分渗透硬脑膜。
我们得出的结论是,只有一小部分施加到硬脑膜上的 CGRP 到达颈内静脉血,并以延迟的方式也到达 CSF。硬脑膜可能构成 CGRP 的屏障,并限制其扩散到蛛网膜下腔的 CSF 中,其中 CGRP 浓度太低而无法引起血管扩张。